Results from EXONDYS 51 clinical studies.
Researchers conducted clinical trials of EXONDYS 51 to review different aspects of the medicine, including whether it triggers skipping of exon 51 on the dystrophin gene. They also analyzed the amount of dystrophin produced, along with its safety profile. EXONDYS 51 was studied in boys who had a confirmed mutation in the dystrophin gene that could be treated by skipping exon 51. Learn what this means.
Designed to skip exon 51.
Three clinical studies looked at whether exon skipping occurred on the dystrophin gene of boys treated with EXONDYS 51. In clinical studies, exon skipping occurred in all 36 evaluated study participants.
Dystrophin levels increased in some clinical trial participants.
A study of 12 boys with Duchenne muscular dystrophy compared the level of dystrophin in their bodies before the first infusion of EXONDYS 51 with the level of dystrophin after 48 weeks of treatment with EXONDYS 51. Weekly infusions of EXONDYS 51 helped the body make a shorter form of the dystrophin protein.
*After 48 weeks, dystrophin levels were an average of 2.8x higher than the level before treatment began, but still remained at a level much lower than that produced by people without Duchenne. In another study of boys treated for 180 weeks, dystrophin levels were an average of 0.93% of the level produced by people without Duchenne. Difference in dystrophin = Week 48 % normal dystrophin/baseline % normal dystrophin.
What do the results tell us?
Additional study results.
** Baseline levels were not available for all participants.
What about risks? Researchers assessed the risks and tolerability of EXONDYS 51. As with any medication, you should discuss the risks and side effects associated with EXONDYS 51 with your doctor.